Monday 12 October 2026 Export all AMGN data to Excel Powerpack

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

414.87 7.43 +1.82%
Market cap
$220.3B
P/E
25.6×
Fwd P/E
22.7×
Dividend yield
2.40%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

21.66 22.84 24.30 22.33
P/S ratio
4.22 4.79 5.10 5.13
P/FCF ratio
13.67 22.97 23.28 20.07
P/Operating CF
32.41 109.85 86.80 48.86
P/B ratio
15.78 20.34 20.67 16.73
EV/Sales
5.48 6.03 6.32 6.27
EV/EBITDA
12.85 14.34 14.83 14.48
EV/FCF
17.74 28.90 28.82 24.52
Current Ratio
1.28 1.14 1.26 1.37
Net Debt/EBITDA
10.66 11.81 11.97 9.36
Debt/Equity
5.67 6.31 6.24 4.90
Earnings Yield
4.62% 4.38% 4.12% 4.48%
Free Cash Flow Yield
7.31% 4.35% 4.30% 4.98%
Free Cash Flow per Share
7.90 1.79 2.74 6.46
Book value per Share
17.88 16.09 17.02 21.64
Free Cash Flow
4,248.00 961.00 1,477.00 3,489.00
EV/EBIT
22.72 24.40 22.26 20.90
Other line items

Show all line items

Columns are period end dates